Home ›
Acute Myeloid (AML) Leukemia Trials ›
NCT07303660
A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients
This is a clinical study aiming to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ZE50-0134 in relapsed and refractory Acute Myeloid Leukemia patients.
Trial Details
NCT ID NCT07303660
Phase PHASE1
Sponsor Lomond Therapeutics Holdings, Inc.
Status RECRUITING
Cancer Type Acute Myeloid (AML) Leukemia
Interventions ZE50-0134 Azacitidine Days 1-7 ZE 50-0134
Locations (sample) Moscow, Moscow, Russia|55.75204,37.61781 Krasnogorsk, Moscow Oblast, Russia|55.81904,37.32984 Velikiy Novgorod, Novgorod Oblast, Russia|58.52131,31.27104 Saint Petersburg, Sankt-Peterburg, Russia|59.93863,30.31413 Saint Petersburg, Sankt-Peterburg, Russia|59.93863,30.31413
Key Eligibility Criteria
1\. Patients must be able to understand and provide written informed consent. 2. AML patients: For the dose escalation and expansion, patients aged… 3\. At the time of Lonitoclax initiation, white blood count (WBC) needs to be \< 25 × 109/L: Hydroxyurea can be used to achieve that level. 4\. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2. 5. Adequate organ function as defined by the following: Aspartate aminotransferase (AST) ≤ 2.5 x upper limit of normal (ULN), alanine aminotransferase (ALT) ≤ 2.5 x ULN. AST and/or ALT may be up to 5 x U…
For full eligibility, visit ClinicalTrials.gov .